

Print Shop # 263518

Regional Pre-Printed Orders for Actively Dying Adults Acute & Long-Term Care



Note: There is a corresponding IMAR for this pre-printed medication order form.

Form ID: DRDO107520A New: June 01, 2022 Page: 1 of 1

DRUG & FOOD ALLERGIES

• Mand	atory □ Optional: Prescriber check (✓) to initiate, cross out and initial any orders not indicated.						
I have determined pa	tient meets all of the criteria:						
 Death anticipated in hours to days (patient must be reviewed daily) 							
 Patient is bed begins 	Patient is bed bound AND taking minimal oral nutrition						
 Patient's progn documented 	r district progressio dita godie or oute have been discussed that the patient or outestate besiden maker and						
Review MOST	status – commonly will be DNR M1						
Assessor's (Acute: M	RP; LTC: MRP/RN/LPN/RPN) Signature: Date:						
Change medical orde	ers to align with goals of care (check all that apply):						
	ine vital signs, weights, glucometer, diagnostic testing, oximetry and blood work						
	eeds – may cause edema and build-up of secretions in lungs						
	elling Foley catheter as required for comfort						
☐ Nurse may pron							
· ·	urrent MEDICATIONS (Do not discontinue fentanyl patch or methadone - see back page)						
Discontinue all	oral medications except:						
SYMPTOMS	MEDICATIONS						
Mild pain and/or Distressing Fever acetaminophen 650 mg PO/rectal Q4H PRN (maximum 4000 mg/24 h from all sources							
	If currently taking opioids:						
	☐ Convert current regular PO opioid to HYDROmorphone subcutaneous Q4H:						
	HYDROmorphone mg subcutaneous Q4H For community pharmacy, dispense 40 doses						
	☐ For breakthrough: HYDROmorphone mg subcutaneous Q1H PRN						
 Pain/Dyspnea	(recommended 10% of total daily dose)						
	For community pharmacy, dispense 40 doses						
	OR						
	If OPIOID NAÏVE (see definition on back page):						
	☐ If opioid naïve, HYDROmorphone 0.25 mg subcutaneous Q1H PRN						
	For community pharmacy, dispense 40 doses						
Distressing	Less sedating: haloperidol 0.5 to 1 mg subcutaneous Q4H PRN						
Restlessness/	(call MRP if more than 2.5 mg from all sources is required in 24 hours) ☐ More sedating: methotrimeprazine 6.25 to 12.5 mg subcutaneous Q4H PRN						
Agitation	(call MRP if requiring more than 25 mg in 12 hours)						
Nausea and/or	□ haloperidol 0.5 to 1 mg subcutaneous Q12H PRN						
Vomiting	(call MRP if more than 2.5 mg from all sources is required in 24 hours)						
Anxiety	□ LORazepam 0.5 to 1 mg sublingual/subcutaneous Q2H PRN (call MRP if using more						
•	than 2 mg in 12 hours). For community pharmacy, dispense 40 doses.						
Upper Airway Secretions	□ atropine 1% eye drop 2 drops sublingual Q2H PRN □ glycopyrrolate 0.4 mg subcutaneous Q4H PRN (maximum 2.4 mg per 24 hours)						
	Note: Each subcutaneous medication requires its own site						
	==== ===========================						

PPO is only active for 2 weeks. After two weeks, if still needed, MRP must review PPO and reorder. Pharmacy requires new signed PPO to provide additional medications beyond 2 weeks.

	Date (dd/mm/yyyy)	Time	Prescriber Signature	Printed Name	College ID#
١					
- 1					

Regional Pre-Printed Orders for Actively Dying Adults Acute & Long-Term Care

Back of Page 1

Tips for Stopping Oral Medication:

- · If patient can no longer swallow, stop all oral medications. Some may need to be converted to another route
- If unsure about medications to stop after reviewing tool for stopping medications at end of life, consult pharmacist or palliative care
- Consider purpose of medications and impact if stopped ie:
 - Do not stop fentanyl patch on dying patients
 - Do not automatically stop steroids can be converted to subcutaneous route
 - · Some diuretics may be beneficial to continue for symptom management of dyspnea

Opioid Equianalgesic Conversion Worksheet

Opioid Naïve definition: patient has received less than 60 mg of oral morphine equivalents daily for less than 7 consecutive days

1. Relative potency comparison (Note: when rotating opioids, reduce final dose by 25%)

Opioid	oxyCODONE	HYDROmorphone		
·	(not available in subcutaneous route)			
Relative Potency	1.5x stronger than morphine	5x stronger than morphine		
Examples:	1 , , , ,	HYDROmorphone 1 mg PO is approximately equal to morphine 5 mg PO		

Hospice Palliative Care Symptoms Guidelines. Principles of Opioid Management, p. 6-7. Fraser Health (2006)

methadone

- methadone: Consult with pharmacist or palliative consult team
- 3. Converting oral oxyCODONE/morphine to subcutaneous HYDROmorphone

o. Convoluing oral expeditional films to deboataneous in Britain	io priorio
STEP 1: If starting with oral oxyCODONE: • Add up total oxyCODONE in last 24 hours • Convert to oral morphine by multiplying above dose by 1.5 STEP 1: If starting with oral morphine: • Add up total oral morphine in last 24 hours	= 24 hour oral morphine dose
STEP 2: Convert 24 hour oral morphine dose to 24 hour subcutaneous dose Divide 24 hour oral morphine dose by 2	= 24 hour subcutaneous morphine dose
STEP 3: Convert 24 hour subcutaneous morphine dose to subcutaneous HYDROmorphone • Divide 24 hour subcutaneous morphine dose by 5	= 24 hour subcutaneous HYDROmorphone dose
STEP 4: Reduce dose by 25% (due to potential for cross tolerance), <u>unless</u> patient having significant pain/dyspnea: • Multiply equianalgesic 24 hour subcutaneous HYDROmorphone dose by 0.75 (i.e. 25% reduction)	= 24 hour subcutaneous HYDROmorphone reduced dose
STEP 5: Determine regular Q4H dose • Divide 24 hour subcutaneous HYDROmorphone dose by 6	= regular subcutaneous HYDROmorphone dose every 4 hours
STEP 6: Determine breakthrough PRN dose • Divide 24 hour subcutaneous HYDROmorphone dose by 10	= breakthrough subcutaneous HYDROmorphone dose every 1 hour PRN

4. Converting oral HYDROmorphone to subcutaneous route

- Step 1: Divide 24 hour oral HYDROmorphone dose by 2 to get subcutaneous dose
- Step 2: Divide 24 hour subcutaneous dose by 6 to get Q4H dose
- Step 3: Breakthrough dose is 10% of 24 hour subcutaneous dose ordered Q1H PRN

5. fentanyl patch

· Continue current dose of fentanyl patch if effective

Breakthrough PRN dosing:

- Divide current dose of fentanyl by 25 to equal breakthrough dose of HYDROmorphone, given subcutaneously every 1 hour PRN
- Example: if patient on fentanyl 50 mcg/h patch, patient will need HYDROmorphone 2 mg subcutaneous Q1H PRN as breakthrough



Room:

Patient:

Regional Interim Medication Administration Record for Actively Dying Adults (PPO Form ID: DRDO107520A)

Acute & Long-Term Care



NOT VERIFIED by Pharmacy

MAR content MUST BE verified for accuracy by comparing with the original order BEFORE using

 Scanning ID: MRAS101785A
 New: June 01, 2022
 Page: 1 of 3

Continues on next page

Date: Allergies:	
SCHEDULED MEDICATIONS	Not given KEY: A=Absent HR=Heart Rate LOA=Leave NA=Not Available NPO N/V R=Refused S=Sleeping
MEDICATION and DIRECTIONS	ADMINISTRATION TIMES
HYDROmorphone inj (DILAUDID EQUIV) mg subcutaneous Q4H For pain and/or dyspnea.	

Page Verified by:

Date/time:

Page: 1



Room:

Patient:

Regional Interim Medication Administration Record for Actively Dying Adults (PPO Form ID: DRDO107520A)

Acute & Long-Term Care



NOT VERIFIED by Pharmacy

MAR content MUST BE verified for accuracy by comparing with the original order BEFORE using

Continues on next page

Date: Allergies:							
PRN MEDICATIONS	Not given KEY: A=Absent HR=Heart Ra	ite LOA=Leave	NA=Not Available	NPO N/V	R=Refused	S=Sleeping	
MEDICATION and DIRECTIONS	ADMINISTRATION TIMES						
acetaminophen tab 650 mg PO Q4H PRN For mild pain and/or distressing fever. Or see alternate rectal order on MAR. Maximum 4000 mg in 24 hours from all sources.							
acetaminophen supp 650 mg rectally Q4H PRN For mild pain and/or distressing fever. Or see alternate PO order on MAR. Maximum 4000 mg in 24 hours from all sources.							
HYDROmorphone inj (DILAUDID EQUIV) mg subcutaneous Q1H PRN For breakthrough pain and/or dyspnea.							
HYDROmorphone inj (DILAUDID EQUIV) 0.25 mg subcutaneous Q1H PRN For pain and/or dyspnea							
haloperidol inj 0.5 to 1 mg subcutaneous Q4H PRN For distressing restlessness/agitation. (Less sedating than methotrimeprazine) (Call MRP if more than 2.5 mg from all sources is required in 24 hours)							
methotrimeprazine inj 6.25 to 12.5 mg subcutaneous Q4H PRN For distressing restlessness/agitation. (More sedating than haloperidol) (Call MRP if requiring more than 25 mg in 12 hours)							

Page Verified by:

Date/time:

Page: 2



Room:

Patient:

Regional Interim Medication Administration Record for Actively Dying Adults (PPO Form ID: DRDO107520A)

Acute & Long-Term Care



NOT VERIFIED by Pharmacy

MAR content MUST BE verified for accuracy by comparing with the original order BEFORE using

 Scanning ID: MRAS101785A
 New: June 01, 2022
 Page: 3 of 3

FINAL PAGE of IMAR

Date: <i>µ</i>	Allergies:							
PRN MEDICATIONS		Not given KEY: A=Absent	HR=Heart Rate	LOA=Leave	NA=Not Available	NPO N/\	/ R=Refused	S=Sleeping
MEDICATION and DIRECT	ONS	ADMINISTRATION TIMES						
haloperidol inj 0.5 to 1 mg subcutaneous Q12H PRN For nausea and/or vomiting. (Call MRP if more than 2.5 mg from all sources is	required in 24 hours)							
LORazepam sublingual tab 0.5 to 1 mg sublingual Q2H PRN For anxiety. Or see alternate subcutaneous order (Call MRP if using more than 2 mg in 12 hours)	on MAR.							
LORazepam inj 0.5 to 1 mg subcutaneous Q2H PRN For anxiety. Or see alternate sublingual order on (Call MRP if using more than 2 mg in 12 hours)	MAR.							
atropine 1% eye drop 2 drops sublingual Q2H PRN For upper airway secretions.								
glycopyrrolate inj 0.4 mg subcutaneous Q4H PRN For upper airway secretions. (Maximum 2.4 mg per 24 hours.)								

Page Verified by:

Date/time:

Page: 3